BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 29978189)

  • 1. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model.
    Pashayan N; Morris S; Gilbert FJ; Pharoah PDP
    JAMA Oncol; 2018 Nov; 4(11):1504-1510. PubMed ID: 29978189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer.
    Callender T; Emberton M; Morris S; Pharoah PDP; Pashayan N
    JAMA Netw Open; 2021 Mar; 4(3):e2037657. PubMed ID: 33704474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
    Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
    PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of the NHS breast screening programme: life table model.
    Pharoah PD; Sewell B; Fitzsimmons D; Bennett HS; Pashayan N
    BMJ; 2013 May; 346():f2618. PubMed ID: 23661112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of Breast Cancer Screening With Magnetic Resonance Imaging for Women at Familial Risk.
    Geuzinge HA; Obdeijn IM; Rutgers EJT; Saadatmand S; Mann RM; Oosterwijk JC; Tollenaar RAEM; de Roy van Zuidewijn DBW; Lobbes MBI; van 't Riet M; Hooning MJ; Ausems MGEM; Loo CE; Wesseling J; Luiten EJT; Zonderland HM; Verhoef C; Heijnsdijk EAM; Tilanus-Linthorst MMA; de Koning HJ;
    JAMA Oncol; 2020 Sep; 6(9):1381-1389. PubMed ID: 32729887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
    Guzauskas GF; Garbett S; Zhou Z; Spencer SJ; Smith HS; Hao J; Hassen D; Snyder SR; Graves JA; Peterson JF; Williams MS; Veenstra DL
    JAMA Netw Open; 2020 Oct; 3(10):e2022874. PubMed ID: 33119106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
    Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
    J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis.
    Gray E; Donten A; Karssemeijer N; van Gils C; Evans DG; Astley S; Payne K
    Value Health; 2017 Sep; 20(8):1100-1109. PubMed ID: 28964442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer : A Cost-Effectiveness Analysis.
    Shih YT; Dong W; Xu Y; Etzioni R; Shen Y
    Ann Intern Med; 2021 May; 174(5):602-612. PubMed ID: 33556275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness analysis of a polygenic risk tailored breast cancer screening programme in Singapore.
    Wong JZY; Chai JH; Yeoh YS; Mohamed Riza NK; Liu J; Teo YY; Wee HL; Hartman M
    BMC Health Serv Res; 2021 Apr; 21(1):379. PubMed ID: 33892705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of Leveraging Social Determinants of Health to Improve Breast, Cervical, and Colorectal Cancer Screening: A Systematic Review.
    Mohan G; Chattopadhyay S
    JAMA Oncol; 2020 Sep; 6(9):1434-1444. PubMed ID: 32556187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Magnetic Resonance Imaging Screening for Women With Extremely Dense Breast Tissue.
    Geuzinge HA; Bakker MF; Heijnsdijk EAM; van Ravesteyn NT; Veldhuis WB; Pijnappel RM; de Lange SV; Emaus MJ; Mann RM; Monninkhof EM; de Koekkoek-Doll PK; van Gils CH; de Koning HJ;
    J Natl Cancer Inst; 2021 Nov; 113(11):1476-1483. PubMed ID: 34585249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population.
    Moore SG; Shenoy PJ; Fanucchi L; Tumeh JW; Flowers CR
    BMC Health Serv Res; 2009 Jan; 9():9. PubMed ID: 19144138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of risk-based breast cancer screening programme, China.
    Sun L; Legood R; Sadique Z; Dos-Santos-Silva I; Yang L
    Bull World Health Organ; 2018 Aug; 96(8):568-577. PubMed ID: 30104797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density.
    Pataky R; Ismail Z; Coldman AJ; Elwood M; Gelmon K; Hedden L; Hislop G; Kan L; McCoy B; Olivotto IA; Peacock S
    J Med Screen; 2014 Dec; 21(4):180-8. PubMed ID: 25186116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
    Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
    Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Population-Based Multigene Testing for Breast and Ovarian Cancer Prevention.
    Guo F; Adekanmbi V; Hsu CD; Berenson AB; Kuo YF; Shih YT
    JAMA Netw Open; 2024 Feb; 7(2):e2356078. PubMed ID: 38353949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.
    Trentham-Dietz A; Kerlikowske K; Stout NK; Miglioretti DL; Schechter CB; Ergun MA; van den Broek JJ; Alagoz O; Sprague BL; van Ravesteyn NT; Near AM; Gangnon RE; Hampton JM; Chandler Y; de Koning HJ; Mandelblatt JS; Tosteson AN;
    Ann Intern Med; 2016 Nov; 165(10):700-712. PubMed ID: 27548583
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.